The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Synopsis
Immune checkpoints are proteins that play an important role in regulating the immune system. In cancer, the immune checkpoints are activated to suppress the anti-tumor activity of the immune system thereby suppressing the immune response against the cancer cells. The study of these proteins and pathways has led to the development of a number of immune checkpoint inhibitors as therapies against cancer. Initial preclinical studies showed that antibody blockade of the immune checkpoint molecule CTLA-4 resulted in successful anti-tumor immune responses in the murine cancer models. This was then followed by studies targeting the PD-1/PD-L1 pathway. Ipilimumab and Yervoy were the first immune checkpoint inhibitors introduced in the market. With the promising results of Yervoy, several anti-PD-1 and anti-PD-L1 antibodies have been developed. Although there are number of other checkpoints that have been studied, such as LAG-3 and TIM-3, the only approved immune checkpoint inhibitors include CTLA-4, PD-1 and PD-L1.
The global Immune Checkpoint Inhibitors market was valued at US$ 12550 million in 2023 and is anticipated to reach US$ 36030 million by 2030, witnessing a CAGR of 16.1% during the forecast period 2024-2030.
North American market for Immune Checkpoint Inhibitors is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Immune Checkpoint Inhibitors is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Immune Checkpoint Inhibitors include Bristol Myer Squibb, AstraZeneca, Merck, Roche / Genentech, Ono Pharmaceutical, Regeneron, Innovent, Hengrui Medicine and Junshi Biosciences, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Immune Checkpoint Inhibitors, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Immune Checkpoint Inhibitors.
Report Scope
The Immune Checkpoint Inhibitors market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Immune Checkpoint Inhibitors market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Immune Checkpoint Inhibitors manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company (Partial List)
- Bristol Myer Squibb
- AstraZeneca
- Merck
- Roche / Genentech
- Ono Pharmaceutical
- Regeneron
- Innovent
- Hengrui Medicine
- Junshi Biosciences
Segment by Type
- PD-1/PD-L1
- CTLA-4
Segment by Application
- Lung Cancer
- Colorectal Cancer
- Breast Cancer
- Prostate Cancer
- Melanoma
- Blood Cancer
- Other
Consumption by Region
- North America (United States, Canada)
- Europe (Germany, France, U.K., Italy, Russia)
- Asia-Pacific (China, Japan, South Korea, India, Australia, China Taiwan, Indonesia, Thailand, Malaysia)
- Latin America (Mexico, Brazil, Argentina)
- Middle East & Africa (Turkey, Saudi Arabia, UAE)
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Immune Checkpoint Inhibitors manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Immune Checkpoint Inhibitors in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index
1 Immune Checkpoint Inhibitors Market Overview
1.1 Product Overview and Scope of Immune Checkpoint Inhibitors
1.2 Immune Checkpoint Inhibitors Segment by Type
1.2.1 Global Immune Checkpoint Inhibitors Market Value Comparison by Type (2024-2030)
1.2.2 PD-1/PD-L1
1.2.3 CTLA-4
1.3 Immune Checkpoint Inhibitors Segment by Application
1.3.1 Global Immune Checkpoint Inhibitors Market Value by Application: (2024-2030)
1.3.2 Lung Cancer
1.3.3 Colorectal Cancer
1.3.4 Breast Cancer
1.3.5 Prostate Cancer
1.3.6 Melanoma
1.3.7 Blood Cancer
1.3.8 Other
1.4 Global Immune Checkpoint Inhibitors Market Size Estimates and Forecasts
1.4.1 Global Immune Checkpoint Inhibitors Revenue 2019-2030
1.4.2 Global Immune Checkpoint Inhibitors Sales 2019-2030
1.4.3 Global Immune Checkpoint Inhibitors Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Immune Checkpoint Inhibitors Market Competition by Manufacturers
2.1 Global Immune Checkpoint Inhibitors Sales Market Share by Manufacturers (2019-2024)
2.2 Global Immune Checkpoint Inhibitors Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Immune Checkpoint Inhibitors Average Price by Manufacturers (2019-2024)
2.4 Global Immune Checkpoint Inhibitors Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Immune Checkpoint Inhibitors, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Immune Checkpoint Inhibitors, Product Type & Application
2.7 Immune Checkpoint Inhibitors Market Competitive Situation and Trends
2.7.1 Immune Checkpoint Inhibitors Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Immune Checkpoint Inhibitors Players Market Share by Revenue
2.7.3 Global Immune Checkpoint Inhibitors Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Immune Checkpoint Inhibitors Retrospective Market Scenario by Region
3.1 Global Immune Checkpoint Inhibitors Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Immune Checkpoint Inhibitors Global Immune Checkpoint Inhibitors Sales by Region: 2019-2030
3.2.1 Global Immune Checkpoint Inhibitors Sales by Region: 2019-2024
3.2.2 Global Immune Checkpoint Inhibitors Sales by Region: 2025-2030
3.3 Global Immune Checkpoint Inhibitors Global Immune Checkpoint Inhibitors Revenue by Region: 2019-2030
3.3.1 Global Immune Checkpoint Inhibitors Revenue by Region: 2019-2024
3.3.2 Global Immune Checkpoint Inhibitors Revenue by Region: 2025-2030
3.4 North America Immune Checkpoint Inhibitors Market Facts & Figures by Country
3.4.1 North America Immune Checkpoint Inhibitors Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Immune Checkpoint Inhibitors Sales by Country (2019-2030)
3.4.3 North America Immune Checkpoint Inhibitors Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Immune Checkpoint Inhibitors Market Facts & Figures by Country
3.5.1 Europe Immune Checkpoint Inhibitors Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Immune Checkpoint Inhibitors Sales by Country (2019-2030)
3.5.3 Europe Immune Checkpoint Inhibitors Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Immune Checkpoint Inhibitors Market Facts & Figures by Country
3.6.1 Asia Pacific Immune Checkpoint Inhibitors Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Immune Checkpoint Inhibitors Sales by Country (2019-2030)
3.6.3 Asia Pacific Immune Checkpoint Inhibitors Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Immune Checkpoint Inhibitors Market Facts & Figures by Country
3.7.1 Latin America Immune Checkpoint Inhibitors Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Immune Checkpoint Inhibitors Sales by Country (2019-2030)
3.7.3 Latin America Immune Checkpoint Inhibitors Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Immune Checkpoint Inhibitors Market Facts & Figures by Country
3.8.1 Middle East and Africa Immune Checkpoint Inhibitors Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Immune Checkpoint Inhibitors Sales by Country (2019-2030)
3.8.3 Middle East and Africa Immune Checkpoint Inhibitors Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Immune Checkpoint Inhibitors Sales by Type (2019-2030)
4.1.1 Global Immune Checkpoint Inhibitors Sales by Type (2019-2024)
4.1.2 Global Immune Checkpoint Inhibitors Sales by Type (2025-2030)
4.1.3 Global Immune Checkpoint Inhibitors Sales Market Share by Type (2019-2030)
4.2 Global Immune Checkpoint Inhibitors Revenue by Type (2019-2030)
4.2.1 Global Immune Checkpoint Inhibitors Revenue by Type (2019-2024)
4.2.2 Global Immune Checkpoint Inhibitors Revenue by Type (2025-2030)
4.2.3 Global Immune Checkpoint Inhibitors Revenue Market Share by Type (2019-2030)
4.3 Global Immune Checkpoint Inhibitors Price by Type (2019-2030)
5 Segment by Application
5.1 Global Immune Checkpoint Inhibitors Sales by Application (2019-2030)
5.1.1 Global Immune Checkpoint Inhibitors Sales by Application (2019-2024)
5.1.2 Global Immune Checkpoint Inhibitors Sales by Application (2025-2030)
5.1.3 Global Immune Checkpoint Inhibitors Sales Market Share by Application (2019-2030)
5.2 Global Immune Checkpoint Inhibitors Revenue by Application (2019-2030)
5.2.1 Global Immune Checkpoint Inhibitors Revenue by Application (2019-2024)
5.2.2 Global Immune Checkpoint Inhibitors Revenue by Application (2025-2030)
5.2.3 Global Immune Checkpoint Inhibitors Revenue Market Share by Application (2019-2030)
5.3 Global Immune Checkpoint Inhibitors Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Bristol Myer Squibb
6.1.1 Bristol Myer Squibb Corporation Information
6.1.2 Bristol Myer Squibb Description and Business Overview
6.1.3 Bristol Myer Squibb Immune Checkpoint Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Bristol Myer Squibb Immune Checkpoint Inhibitors Product Portfolio
6.1.5 Bristol Myer Squibb Recent Developments/Updates
6.2 AstraZeneca
6.2.1 AstraZeneca Corporation Information
6.2.2 AstraZeneca Description and Business Overview
6.2.3 AstraZeneca Immune Checkpoint Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.2.4 AstraZeneca Immune Checkpoint Inhibitors Product Portfolio
6.2.5 AstraZeneca Recent Developments/Updates
6.3 Merck
6.3.1 Merck Corporation Information
6.3.2 Merck Description and Business Overview
6.3.3 Merck Immune Checkpoint Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Merck Immune Checkpoint Inhibitors Product Portfolio
6.3.5 Merck Recent Developments/Updates
6.4 Roche / Genentech
6.4.1 Roche / Genentech Corporation Information
6.4.2 Roche / Genentech Description and Business Overview
6.4.3 Roche / Genentech Immune Checkpoint Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Roche / Genentech Immune Checkpoint Inhibitors Product Portfolio
6.4.5 Roche / Genentech Recent Developments/Updates
6.5 Ono Pharmaceutical
6.5.1 Ono Pharmaceutical Corporation Information
6.5.2 Ono Pharmaceutical Description and Business Overview
6.5.3 Ono Pharmaceutical Immune Checkpoint Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Ono Pharmaceutical Immune Checkpoint Inhibitors Product Portfolio
6.5.5 Ono Pharmaceutical Recent Developments/Updates
6.6 Regeneron
6.6.1 Regeneron Corporation Information
6.6.2 Regeneron Description and Business Overview
6.6.3 Regeneron Immune Checkpoint Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Regeneron Immune Checkpoint Inhibitors Product Portfolio
6.6.5 Regeneron Recent Developments/Updates
6.7 Innovent
6.6.1 Innovent Corporation Information
6.6.2 Innovent Description and Business Overview
6.6.3 Innovent Immune Checkpoint Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Innovent Immune Checkpoint Inhibitors Product Portfolio
6.7.5 Innovent Recent Developments/Updates
6.8 Hengrui Medicine
6.8.1 Hengrui Medicine Corporation Information
6.8.2 Hengrui Medicine Description and Business Overview
6.8.3 Hengrui Medicine Immune Checkpoint Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Hengrui Medicine Immune Checkpoint Inhibitors Product Portfolio
6.8.5 Hengrui Medicine Recent Developments/Updates
6.9 Junshi Biosciences
6.9.1 Junshi Biosciences Corporation Information
6.9.2 Junshi Biosciences Description and Business Overview
6.9.3 Junshi Biosciences Immune Checkpoint Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Junshi Biosciences Immune Checkpoint Inhibitors Product Portfolio
6.9.5 Junshi Biosciences Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Immune Checkpoint Inhibitors Industry Chain Analysis
7.2 Immune Checkpoint Inhibitors Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Immune Checkpoint Inhibitors Production Mode & Process
7.4 Immune Checkpoint Inhibitors Sales and Marketing
7.4.1 Immune Checkpoint Inhibitors Sales Channels
7.4.2 Immune Checkpoint Inhibitors Distributors
7.5 Immune Checkpoint Inhibitors Customers
8 Immune Checkpoint Inhibitors Market Dynamics
8.1 Immune Checkpoint Inhibitors Industry Trends
8.2 Immune Checkpoint Inhibitors Market Drivers
8.3 Immune Checkpoint Inhibitors Market Challenges
8.4 Immune Checkpoint Inhibitors Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
